Today we're going to take a look at the well-established Bio-Techne Corporation (NASDAQ:TECH). The company's stock saw a significant share price rise of 21% in the past couple of months on the NASDAQGS. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. With many analysts covering the large-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Today we will analyse the most recent data on Bio-Techne’s outlook and valuation to see if the opportunity still exists.

View our latest analysis for Bio-Techne

What Is Bio-Techne Worth?

The share price seems sensible at the moment according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. In this instance, we’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. We find that Bio-Techne’s ratio of 52.17x is trading slightly above its industry peers’ ratio of 44.15x, which means if you buy Bio-Techne today, you’d be paying a relatively sensible price for it. And if you believe that Bio-Techne should be trading at this level in the long run, then there should only be a fairly immaterial downside vs other industry peers. Although, there may be an opportunity to buy in the future. This is because Bio-Techne’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

What kind of growth will Bio-Techne generate?

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. However, with a relatively muted profit growth of 9.6% expected over the next couple of years, growth doesn’t seem like a key driver for a buy decision for Bio-Techne, at least in the short term.

What This Means For You

Are you a shareholder? It seems like the market has already priced in TECH’s growth outlook, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at TECH? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio?